TY - JOUR
T1 - Sex hormone-binding globulin
T2 - biomarker and hepatokine?
AU - Simons, Pomme I. H. G.
AU - Valkenburg, Olivier
AU - Stehouwer, Coen D. A.
AU - Brouwers, Martijn C. G. J.
N1 - Funding Information:
This work was supported by a research grant from the European Foundation for the Study of Diabetes (EFSD)/Sanofi.
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/8
Y1 - 2021/8
N2 - Over the past decade, there have been important breakthroughs in our understanding of the regulation and function of sex hormone-binding globulin (SHBG). A recent genome-wide association and Mendelian randomization study has provided new insights at the population level. Thorough study of genetic variants affecting serum SHBG has identified de novo lipogenesis as one of the mechanistic links between the metabolic syndrome and reduced serum SHBG levels in humans. Furthermore, careful deduction of the Mendelian randomization results suggests a direct, causal role for SHBG in the pathogenesis of type 2 diabetes, as a hepatokine, in women. These findings prompt the development of SHBG-raising therapies as a means to prevent or treat disorders such as type 2 diabetes and polycystic ovary syndrome.
AB - Over the past decade, there have been important breakthroughs in our understanding of the regulation and function of sex hormone-binding globulin (SHBG). A recent genome-wide association and Mendelian randomization study has provided new insights at the population level. Thorough study of genetic variants affecting serum SHBG has identified de novo lipogenesis as one of the mechanistic links between the metabolic syndrome and reduced serum SHBG levels in humans. Furthermore, careful deduction of the Mendelian randomization results suggests a direct, causal role for SHBG in the pathogenesis of type 2 diabetes, as a hepatokine, in women. These findings prompt the development of SHBG-raising therapies as a means to prevent or treat disorders such as type 2 diabetes and polycystic ovary syndrome.
KW - DE-NOVO LIPOGENESIS
KW - BODY-MASS INDEX
KW - METABOLIC-SYNDROME
KW - CONFERS SUSCEPTIBILITY
KW - POSTMENOPAUSAL WOMEN
KW - REPLACEMENT THERAPY
KW - WIDE ASSOCIATION
KW - COMMON VARIANT
KW - P446L VARIANT
KW - OBESE WOMEN
U2 - 10.1016/j.tem.2021.05.002
DO - 10.1016/j.tem.2021.05.002
M3 - (Systematic) Review article
C2 - 34052096
SN - 1043-2760
VL - 32
SP - 544
EP - 553
JO - Trends in Endocrinology and Metabolism
JF - Trends in Endocrinology and Metabolism
IS - 8
ER -